$EYEN
EYENOVIA, INC. Stock $eyen

$eyen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000141057824000226 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$4.993K	$2.590K	$3.790K
YoY Change
Cost Of Revenue	$4.993K	$2.590K	$3.790K
YoY Change
Gross Profit	$0.00	$0.00	$0.00
YoY Change
Gross Profit Margin	0.0%	0.0%	0.0%
Selling, General & Admin	$3.835M	$3.402M	$12.62M
YoY Change	30.45%	7.32%	-7.2%
% of Gross Profit
Research & Development	$4.432M	$4.065M	$12.01M
YoY Change	75.72%	78.16%	-10.26%
% of Gross Profit
Depreciation & Amortization	$247.7K	$277.5K	$783.2K
YoY Change	292.48%	253.41%	154.76%
% of Gross Profit
Operating Expenses	$10.27M	$7.467M	$25.41M
YoY Change	88.08%	38.98%	-5.59%
Operating Profit	-$10.27M	-$7.467M	-$25.41M
YoY Change	88.08%	38.98%	-5.59%
Interest Expense	$678.7K	-$482.0K	-$1.678M
YoY Change	49.48%	-43.41%	-221.61%
% of Operating Profit
Other Income/Expense, Net	-$655.3K	-$18.63K	-$176.4K
YoY Change	-1023.02%	-118.54%	-189.51%
Pretax Income	-$10.92M	-$7.967M	-$27.26M
YoY Change	90.28%	30.11%	-2.68%
Income Tax
% Of Pretax Income
Net Earnings	-$10.92M	-$7.967M	-$27.26M
YoY Change	90.3%	30.11%	-2.68%
Net Earnings / Revenue	-218748.27%	-307611.58%	-719290.24%
Basic Earnings Per Share	-$0.23		-$0.66
Diluted Earnings Per Share	-$0.23	-$0.16	-$0.66
COMMON SHARES
Basic Shares Outstanding	47.39M	44.12M	41.03M
Diluted Shares Outstanding	46.61M		41.03M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.976M	$14.85M	$14.85M
YoY Change	-57.09%	-35.39%	-35.39%
Cash & Equivalents	$8.000M	$14.80M
Short-Term Investments
Other Short-Term Assets	$2.373M	$5.123M	$5.123M
YoY Change	-49.72%	82.02%	82.02%
Inventory	$3.514M	$109.8K	$109.8K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.45M	$20.71M	$20.71M
YoY Change	-42.02%	-25.09%	-25.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.156M	$5.041M	$5.041M
YoY Change	46.58%	289.24%	94.88%
Goodwill
YoY Change
Intangibles	$6.123M	$2.123M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$908.6K	$908.6K	$908.6K
YoY Change	41.2%	25.1%	25.1%
Total Long-Term Assets	$11.73M	$8.073M	$8.073M
YoY Change	167.39%	137.86%	137.86%
TOTAL ASSETS
Total Short-Term Assets	$14.45M	$20.71M	$20.71M
Total Long-Term Assets	$11.73M	$8.073M	$8.073M
Total Assets	$26.18M	$28.78M	$28.78M
YoY Change	-10.69%	-7.27%	-7.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.145M	$1.753M	$1.753M
YoY Change	53.01%	22.75%	22.75%
Accrued Expenses	$6.143M	$2.413M	$2.413M
YoY Change	303.22%	-9.98%	-9.98%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$8.155M	$5.329M	$5.329M
YoY Change	569.02%	1427.49%	1427.49%
Total Short-Term Liabilities	$16.46M	$9.530M	$9.530M
YoY Change	235.84%	111.21%	111.21%
LONG-TERM LIABILITIES
Long-Term Debt	$6.759M	$8.957M	$8.957M
YoY Change	-9.4%	6.86%	6.86%
Other Long-Term Liabilities	$1.140M	$1.293M	$1.293M
YoY Change	0.55%	42.42%	42.42%
Total Long-Term Liabilities	$7.899M	$10.25M	$10.25M
YoY Change	-8.09%	10.34%	10.34%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.46M	$9.530M	$9.530M
Total Long-Term Liabilities	$7.899M	$10.25M	$10.25M
Total Liabilities	$24.36M	$19.78M	$19.78M
YoY Change	80.5%	43.32%	43.32%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.4M	-$145.5M
YoY Change	26.16%	23.1%
Common Stock	$4.738K	$4.555K
YoY Change	24.72%	24.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.039M	$5.450M
YoY Change	-87.18%
Treasury Stock Shares
Shareholders Equity	$1.818M	$8.999M	$8.999M
YoY Change
Total Liabilities & Shareholders Equity	$26.18M	$28.78M	$28.78M
YoY Change	-10.69%	-7.27%	-7.27%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$10.92M	-$7.967M	-$27.26M
YoY Change	90.3%	30.11%	-2.68%
Depreciation, Depletion And Amortization	$247.7K	$277.5K	$783.2K
YoY Change	292.48%	253.41%	154.76%
Cash From Operating Activities	-$9.900M	-$6.322M	-$23.84M
YoY Change	41.43%	16.97%	-5.03%
INVESTING ACTIVITIES
Capital Expenditures	$114.1K	$145.2K	$2.848M
YoY Change	-87.61%	368.64%	426.98%
Acquisitions
YoY Change
Other Investing Activities		-$2.950K	-$1.123M
YoY Change		-98.95%	235.82%
Cash From Investing Activities	-$114.1K	-$145.2K	-$3.971M
YoY Change	-86.38%	-53.42%	353.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$16.76M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.133M	614.3K	19.79M
YoY Change	-7.84%	-81.42%	-7.97%
NET CHANGE
Cash From Operating Activities	-9.900M	-6.322M	-23.84M
Cash From Investing Activities	-114.1K	-145.2K	-3.971M
Cash From Financing Activities	3.133M	614.3K	19.79M
Net Change In Cash	-6.873M	-5.853M	-8.014M
YoY Change	56.3%	142.86%	79.16%
FREE CASH FLOW
Cash From Operating Activities	-$9.900M	-$6.322M	-$23.84M
Capital Expenditures	$114.1K	$145.2K	$2.848M
Free Cash Flow	-$10.01M	-$6.467M	-$26.68M
YoY Change	26.43%	18.98%	4.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36668980
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45553026
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001682639
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38365
CY2023	dei	Entity Registrant Name EntityRegistrantName	EYENOVIA, INC.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1178401
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	295 Madison Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2400
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	NEW YORK
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
CY2023	dei	City Area Code CityAreaCode	833
CY2023	dei	Local Phone Number LocalPhoneNumber	393-6684
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 Par Value
CY2023	dei	Trading Symbol TradingSymbol	EYEN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q2	dei	Entity Public Float EntityPublicFloat	88000000.0
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47386349
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14849057
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22863520
CY2023Q4	us-gaap	Inventory Net InventoryNet	109798
CY2023Q4	eyen	Deferred Clinical Supply Costs DeferredClinicalSupplyCosts	4256793
CY2022Q4	eyen	Deferred Clinical Supply Costs DeferredClinicalSupplyCosts	2284931
CY2023Q4	eyen	License Fee And Expense Reimbursements Receivables LicenseFeeAndExpenseReimbursementsReceivables	123833
CY2022Q4	eyen	License Fee And Expense Reimbursements Receivables LicenseFeeAndExpenseReimbursementsReceivables	1183786
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1506
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	119550
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1365731
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1190719
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20706718
CY2022Q4	us-gaap	Assets Current AssetsCurrent	27642506
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3374384
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1295115
CY2023Q4	eyen	Security Deposits SecurityDeposits	197168
CY2022Q4	eyen	Security Deposits SecurityDeposits	80874
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2122945
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1666718
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1291592
CY2023Q4	eyen	Equipment Deposits EquipmentDeposits	711441
CY2022Q4	eyen	Equipment Deposits EquipmentDeposits	726326
CY2023Q4	us-gaap	Assets Assets	28779374
CY2022Q4	us-gaap	Assets Assets	31036413
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1753172
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1428283
CY2023Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1658613
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	1747191
CY2023Q4	eyen	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	287928
CY2022Q4	eyen	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	503076
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	501250
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	484882
CY2023Q4	eyen	Notes Payable Unamortized Discount Current NotesPayableUnamortizedDiscountCurrent	503914
CY2022Q4	eyen	Notes Payable Unamortized Discount Current NotesPayableUnamortizedDiscountCurrent	33885
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	5329419
CY2022Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	174448
CY2023Q4	eyen	Convertible Notes Payable Unamortized Discount Current ConvertibleNotesPayableUnamortizedDiscountCurrent	0
CY2022Q4	eyen	Convertible Notes Payable Unamortized Discount Current ConvertibleNotesPayableUnamortizedDiscountCurrent	33885
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	174448
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9530382
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4512328
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1292667
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	907644
CY2023Q4	eyen	Notes Payable Unamortized Discount Noncurrent NotesPayableUnamortizedDiscountNoncurrent	448367
CY2022Q4	eyen	Notes Payable Unamortized Discount Noncurrent NotesPayableUnamortizedDiscountNoncurrent	813229
CY2023Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	4355800
CY2022Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	4190938
CY2023Q4	eyen	Convertible Notes Payable Unamortized Discount Noncurrent ConvertibleNotesPayableUnamortizedDiscountNoncurrent	398569
CY2022Q4	eyen	Convertible Notes Payable Unamortized Discount Noncurrent ConvertibleNotesPayableUnamortizedDiscountNoncurrent	813229
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4601431
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4190938
CY2023Q4	us-gaap	Liabilities Liabilities	19780280
CY2022Q4	us-gaap	Liabilities Liabilities	13801848
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45553026
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36668980
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4555
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3667
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	154486098
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	135461361
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-145491559
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118230463
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8999094
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17234565
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28779374
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31036413
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3787
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	3787
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12975832
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13378680
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12430614
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13532835
CY2023	us-gaap	Operating Expenses OperatingExpenses	25406446
CY2022	us-gaap	Operating Expenses OperatingExpenses	26911515
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-25406446
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-26911515
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-176411
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	197090
CY2023	us-gaap	Interest Expense InterestExpense	2371851
CY2022	us-gaap	Interest Expense InterestExpense	1380058
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	693612
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	83326
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1854650
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1099642
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27261096
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28011157
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41032970
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41032970
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33649747
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33649747
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20466615
CY2022	eyen	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	14897908
CY2022	eyen	Stock Issued During Period Value Debt Financing StockIssuedDuringPeriodValueDebtFinancing	859733
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	44375
CY2022	eyen	Stock Issued At Market Offering During Period Value New Issues StockIssuedAtMarketOfferingDuringPeriodValueNewIssues	5281776
CY2022	eyen	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	18701
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3765364
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28011157
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17234565
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10886114
CY2023	eyen	Stock Issued During Period Value Licensing Agreement StockIssuedDuringPeriodValueLicensingAgreement	1000000
CY2023	eyen	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	22529
CY2023	eyen	Stock Issued At Market Offering During Period Value New Issues StockIssuedAtMarketOfferingDuringPeriodValueNewIssues	4591892
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27200
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2497890
CY2023	eyen	Adjustments To Additional Paid In Capital Warrant Modification Incremental Value AdjustmentsToAdditionalPaidInCapitalWarrantModificationIncrementalValue	1738700
CY2023	eyen	Adjustments To Additional Paid In Capital Warrant Modification Issuance Costs AdjustmentsToAdditionalPaidInCapitalWarrantModificationIssuanceCosts	1738700
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27261096
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	8999094
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27261096
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28011157
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2497890
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3765364
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	783208
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	307430
CY2023	eyen	Amortization Of Debt Discount AmortizationOfDebtDiscount	681860
CY2022	eyen	Amortization Of Debt Discount AmortizationOfDebtDiscount	411918
CY2022	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	209040
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	12218
CY2023	eyen	Provision For Returned Clinical Supplies ProvisionForReturnedClinicalSupplies	400000
CY2023	eyen	Non Cash Rent Expense NonCashRentExpense	529311
CY2022	eyen	Non Cash Rent Expense NonCashRentExpense	474778
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-434128
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-219555
CY2023	eyen	Increase Decrease In License Fee And Expense Reimbursements Receivables IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables	-1059953
CY2022	eyen	Increase Decrease In License Fee And Expense Reimbursements Receivables IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables	-621279
CY2023	eyen	Increase Decrease In Deferred Clinical Supply Costs IncreaseDecreaseInDeferredClinicalSupplyCosts	2271862
CY2022	eyen	Increase Decrease In Deferred Clinical Supply Costs IncreaseDecreaseInDeferredClinicalSupplyCosts	2284931
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	122016
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	1750
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-81389
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	324889
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-185821
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-88578
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	203573
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-315148
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-342643
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-503046
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-412478
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23836539
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25105482
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2847592
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	540360
CY2022	eyen	Vendor Deposits For Property Plant And Equipment VendorDepositsForPropertyPlantAndEquipment	334385
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1122945
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3970537
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-874745
CY2023	eyen	Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering	11977468
CY2022	eyen	Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering	14981299
CY2023	eyen	Payments For Repurchase Of Public Offering PaymentsForRepurchaseOfPublicOffering	1091354
CY2022	eyen	Payments For Repurchase Of Public Offering PaymentsForRepurchaseOfPublicOffering	83391
CY2023	eyen	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	4733909
CY2022	eyen	Proceeds From Issuance Of Common Stock At Market Offering ProceedsFromIssuanceOfCommonStockAtMarketOffering	5445130
CY2023	eyen	Payments Of Stock Issuance Costs At Market Offering PaymentsOfStockIssuanceCostsAtMarketOffering	142017
CY2022	eyen	Payments Of Stock Issuance Costs At Market Offering PaymentsOfStockIssuanceCostsAtMarketOffering	163354
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27200
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22529
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	18701
CY2023	eyen	Proceeds From Issuance Of Debt And Equity Related Party ProceedsFromIssuanceOfDebtAndEquityRelatedParty	5000000
CY2022	eyen	Proceeds From Issuance Of Debt And Equity Related Party ProceedsFromIssuanceOfDebtAndEquityRelatedParty	10000000
CY2022	eyen	Payments Of Stock Issuance Costs Related Party PaymentsOfStockIssuanceCostsRelatedParty	46836
CY2023	eyen	Payments Of Debt Issuance Costs Related Party PaymentsOfDebtIssuanceCostsRelatedParty	125982
CY2022	eyen	Payments Of Debt Issuance Costs Related Party PaymentsOfDebtIssuanceCostsRelatedParty	469320
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	609140
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	8175332
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19792613
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21506897
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8014463
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4473330
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22863520
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27336850
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14849057
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22863520
CY2023	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	1690548
CY2022	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	315550
CY2023	eyen	Purchase Of Insurance Premium Financed By Short Term Note Payable PurchaseOfInsurancePremiumFinancedByShortTermNotePayable	609140
CY2022	eyen	Purchase Of Insurance Premium Financed By Short Term Note Payable PurchaseOfInsurancePremiumFinancedByShortTermNotePayable	675332
CY2022	eyen	Recognition Of Right Of Use Asset For Lease Liability Upon Adoption Of Accounting Standard Update RecognitionOfRightOfUseAssetForLeaseLiabilityUponAdoptionOfAccountingStandardUpdate	618906
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1186098
CY2023	eyen	Right Of Use Asset And Lease Liabilities Recognized Upon Lease Renewal RightOfUseAssetAndLeaseLiabilitiesRecognizedUponLeaseRenewal	904437
CY2023	us-gaap	Escrow Deposit Disbursements Related To Property Acquisition1 EscrowDepositDisbursementsRelatedToPropertyAcquisition1	14885
CY2023	eyen	Original Issue Discount On Notes Payable OriginalIssueDiscountOnNotesPayable	212500
CY2023	eyen	Adjustments To Additional Paid In Capital Warrant Modification Incremental Value AdjustmentsToAdditionalPaidInCapitalWarrantModificationIncrementalValue	1738700
CY2023	us-gaap	Stock Issued1 StockIssued1	1000000
CY2023	eyen	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	2
CY2022Q4	eyen	Common Stocks Discount On Shares CommonStocksDiscountOnShares	859733
CY2023	eyen	Issuance Of Common Stock Related To Vested Restricted Stock Units IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits	4
CY2022	eyen	Issuance Of Common Stock Related To Vested Restricted Stock Units IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits	11
CY2023	eyen	Percentage Of Success Rate Of Optejet PercentageOfSuccessRateOfOptejet	0.98
CY2023	eyen	Percentage Of Successful Rate Of Traditional Eye Drops PercentageOfSuccessfulRateOfTraditionalEyeDrops	0.50
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14800000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-145500000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27300000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28000000.0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23800000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25100000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for deferred tax assets, revenue recognition, the recoverability and useful lives of long-lived assets, the realization of inventories and deferred clinical supply costs, the recovery of deferred costs and the deferral of revenues. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 2 - Summary of Significant Accounting Policies — Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company’s common stock. </p>
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	5450118
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	14243870
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	22613520
CY2023	eyen	Provision For Returned Clinical Supplies ProvisionForReturnedClinicalSupplies	400000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30683
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	79115
CY2023Q4	us-gaap	Inventory Net InventoryNet	109798
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-27261096
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28011157
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27261096
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28011157
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	39907873
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33252644
CY2023	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1042033
CY2022	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	333037
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	83064
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	64066
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41032970
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41032970
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33649747
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33649747
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18666697
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11641198
CY2023Q4	eyen	Payroll Taxes Receivable PayrollTaxesReceivable	500684
CY2022Q4	eyen	Payroll Taxes Receivable PayrollTaxesReceivable	660891
CY2023Q4	eyen	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	421056
CY2022Q4	eyen	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	2521
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	167338
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	201082
CY2023Q4	eyen	Prepaid Conference Expenses Current PrepaidConferenceExpensesCurrent	123556
CY2022Q4	eyen	Prepaid Conference Expenses Current PrepaidConferenceExpensesCurrent	97743
CY2023Q4	eyen	Prepaid General And Administrative Expenses PrepaidGeneralAndAdministrativeExpenses	85938
CY2022Q4	eyen	Prepaid General And Administrative Expenses PrepaidGeneralAndAdministrativeExpenses	87982
CY2023Q4	eyen	Prepaid Patent Expense PrepaidPatentExpense	48409
CY2022Q4	eyen	Prepaid Patent Expense PrepaidPatentExpense	38796
CY2023Q4	eyen	Prepaid Rent And Security Deposit PrepaidRentAndSecurityDeposit	18750
CY2022Q4	eyen	Prepaid Rent And Security Deposit PrepaidRentAndSecurityDeposit	74959
CY2023Q4	us-gaap	Other Assets OtherAssets	0
CY2022Q4	us-gaap	Other Assets OtherAssets	26745
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1365731
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1190719
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4793430
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1930953
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1419046
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	635838
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3374384
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1295115
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1302997
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1447643
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	355616
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	299548
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1658613
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1747191
CY2023Q4	eyen	Accrued Rework Of Clinical Supply Returns Current AccruedReworkOfClinicalSupplyReturnsCurrent	100000
CY2022Q4	eyen	Accrued Rework Of Clinical Supply Returns Current AccruedReworkOfClinicalSupplyReturnsCurrent	0
CY2023Q4	eyen	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	89872
CY2022Q4	eyen	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	35524
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	63028
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	320000
CY2023Q4	eyen	Credit Card Payable CreditCardPayable	27193
CY2022Q4	eyen	Credit Card Payable CreditCardPayable	50639
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7835
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4385
CY2023Q4	eyen	Accrued Leasehold Improvements Current AccruedLeaseholdImprovementsCurrent	0
CY2022Q4	eyen	Accrued Leasehold Improvements Current AccruedLeaseholdImprovementsCurrent	92528
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	287928
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	503076
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5833333
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	503914
CY2023Q4	eyen	Notes Payable Current Net Of Debt Discount Current Current Portion NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion	5329419
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	416666
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	67770
CY2022Q4	eyen	Notes Payable Current Net Of Debt Discount Current Current Portion NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion	348896
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9804167
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	846936
CY2023Q4	eyen	Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion	8957231
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	10008334
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1626458
CY2022Q4	eyen	Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion	8381876
CY2022Q4	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8025000
CY2022Q4	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	7500000
CY2022Q4	eyen	Debt Instrument Final Payment DebtInstrumentFinalPayment	375000
CY2022Q4	eyen	Percentage Of Prepayment Fees PercentageOfPrepaymentFees	0.02
CY2022Q4	eyen	Prepayment Fees Amount PrepaymentFeesAmount	-150000
CY2022Q4	eyen	Restricted Cash Used For Repayment Of Loan RestrictedCashUsedForRepaymentOfLoan	7875000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5381793
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5879362
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-849201
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-208806
CY2023	eyen	Deferred Income Tax Expense Benefit Before Adjustments For Change In Valuation Allowance DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance	4532592
CY2022	eyen	Deferred Income Tax Expense Benefit Before Adjustments For Change In Valuation Allowance DeferredIncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance	5670556
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4532592
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5670556
CY2023	eyen	Effective Income Tax Rate Reconciliation Net At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate	-0.210
CY2022	eyen	Effective Income Tax Rate Reconciliation Net At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationNetAtFederalStatutoryIncomeTaxRate	-0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.025
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.010
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.013
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.019
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.013
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.166
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.203
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23804461
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20165693
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	528894
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	799182
CY2023Q4	eyen	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	3581962
CY2022Q4	eyen	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	2304110
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2080864
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2089014
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	688746
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	633151
CY2023Q4	eyen	Deferred Tax Assets Lease Liabilitites DeferredTaxAssetsLeaseLiabilitites	376883
CY2022Q4	eyen	Deferred Tax Assets Lease Liabilitites DeferredTaxAssetsLeaseLiabilitites	327276
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	31061809
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26318426
CY2023Q4	eyen	Deferred Tax Assets Liability Property And Equipment DeferredTaxAssetsLiabilityPropertyAndEquipment	348323
CY2022Q4	eyen	Deferred Tax Assets Liability Property And Equipment DeferredTaxAssetsLiabilityPropertyAndEquipment	184138
CY2023Q4	eyen	Deferred Tax Liabilities Rights Of Use Assets DeferredTaxLiabilitiesRightsOfUseAssets	-350160
CY2022Q4	eyen	Deferred Tax Liabilities Rights Of Use Assets DeferredTaxLiabilitiesRightsOfUseAssets	-303554
CY2023Q4	eyen	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	30363326
CY2022Q4	eyen	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	25830734
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30363326
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	25830734
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4532592
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5670556
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	10800000
CY2023	eyen	Operating Loss Carry Forwards Expiration Term OperatingLossCarryForwardsExpirationTerm	2034 to 2037
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	93500000
CY2023Q4	eyen	Net Operating Loss Limit For Utilization As Per Internal Revenue Code NetOperatingLossLimitForUtilizationAsPerInternalRevenueCode	35000000
CY2023Q4	eyen	Net Operating Loss Annual Utilization Limit As Per Internal Revenue Code NetOperatingLossAnnualUtilizationLimitAsPerInternalRevenueCode	918000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	503046
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	412478
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	904437
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1186098
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y14D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	660923
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	675400
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	560996
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	214619
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2111938
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	318021
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1793917
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	501250
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1292667
CY2020Q2	eyen	Percentage Of Royalty To Be Transferred Range2 PercentageOfRoyaltyToBeTransferredRange2	0.40
CY2020Q2	eyen	Percentage Of Royalty To Be Transferred Range1 PercentageOfRoyaltyToBeTransferredRange1	0.30
CY2020Q2	eyen	Percentage Of Royalty To Be Transferred Range2 PercentageOfRoyaltyToBeTransferredRange2	0.40
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	6000000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6087845
CY2022Q4	eyen	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	3.37
CY2023	eyen	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	7091688
CY2023	eyen	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	1.52
CY2023	eyen	Class Of Warrant Or Right New Repriced ClassOfWarrantOrRightNewRepriced	-4870130
CY2023	eyen	Class Of Warrant Or Right Old Repriced Weighted Average Exercise Price ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice	3.54
CY2023	eyen	Class Of Warrant Or Right Old Repriced ClassOfWarrantOrRightOldRepriced	4870130
CY2023	eyen	Class Of Warrant Or Right New Repriced Weighted Average Exercise Price ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice	2.23
CY2023	eyen	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	2252979
CY2023	eyen	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	0.01
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10926554
CY2023Q4	eyen	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	2.28
CY2023	eyen	Class Of Warrant Or Right Outstanding Weighted Average Remaining Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife	P4Y9M18D
CY2023Q4	eyen	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	1217715
CY2023Q4	eyen	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	2.69
CY2023	eyen	Class Of Warrant Or Right Exercisable Weighted Average Remaining Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife	P1Y8M12D
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10926554
CY2023	eyen	Class Of Warrant Or Right Exercisable Weighted Average Remaining Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife	P1Y8M12D
CY2023Q4	eyen	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	1217715
CY2023Q4	eyen	Class Of Warrant Or Rights Multiplied By Remaining Number Of Years ClassOfWarrantOrRightsMultipliedByRemainingNumberOfYears	2023685
CY2023Q4	eyen	Class Of Warrant Or Rights Multiplied By Exercise Price ClassOfWarrantOrRightsMultipliedByExercisePrice	3272767
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2252979
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	22529
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1870130
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	18701
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2497890
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3765364
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	172800
CY2022Q4	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice	1.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	106019
CY2023	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice	2.12
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	150578
CY2023	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice	1.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	22222
CY2023	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsForfeitedInPeriodWeightedAverageExercisePrice	1.80
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	106019
CY2023Q4	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice	2.12
CY2023	eyen	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber	135745
CY2023	eyen	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice	2.22
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	10000
CY2023	eyen	Stock Issued During Period Shares Cashless Stock Options Exercised StockIssuedDuringPeriodSharesCashlessStockOptionsExercised	20749
CY2023	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	58250
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5306377
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	3980102
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.65
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.60
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1812323
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2019Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019Q2	us-gaap	Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage	0.04
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	218170
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	208006

Files In Submission

Name	View Source	Status
0001410578-24-000226-index-headers.html	Edgar Link	pending
0001410578-24-000226-index.html	Edgar Link	pending
0001410578-24-000226.txt	Edgar Link	pending
0001410578-24-000226-xbrl.zip	Edgar Link	pending
eyen-20231231.xsd	Edgar Link	pending
eyen-20231231x10k.htm	Edgar Link	pending
eyen-20231231x10k002.jpg	Edgar Link	pending
eyen-20231231x10k003.jpg	Edgar Link	pending
eyen-20231231x10k004.jpg	Edgar Link	pending
eyen-20231231x10k005.jpg	Edgar Link	pending
eyen-20231231x10k006.jpg	Edgar Link	pending
eyen-20231231x10k007.jpg	Edgar Link	pending
eyen-20231231x10k008.jpg	Edgar Link	pending
eyen-20231231x10k009.jpg	Edgar Link	pending
eyen-20231231x10k010.jpg	Edgar Link	pending
eyen-20231231x10k011.jpg	Edgar Link	pending
eyen-20231231x10k012.jpg	Edgar Link	pending
eyen-20231231x10k013.jpg	Edgar Link	pending
eyen-20231231x10k014.jpg	Edgar Link	pending
eyen-20231231x10k015.jpg	Edgar Link	pending
eyen-20231231x10k016.jpg	Edgar Link	pending
eyen-20231231x10k017.jpg	Edgar Link	pending
eyen-20231231x10k018.jpg	Edgar Link	pending
eyen-20231231x10k019.jpg	Edgar Link	pending
eyen-20231231xex10d38.htm	Edgar Link	pending
eyen-20231231xex23d1.htm	Edgar Link	pending
eyen-20231231xex31d1.htm	Edgar Link	pending
eyen-20231231xex31d2.htm	Edgar Link	pending
eyen-20231231xex32d1.htm	Edgar Link	pending
eyen-20231231xex32d2.htm	Edgar Link	pending
eyen-20231231xex97d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
eyen-20231231_def.xml	Edgar Link	unprocessable
eyen-20231231_lab.xml	Edgar Link	unprocessable
eyen-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
eyen-20231231x10k_htm.xml	Edgar Link	completed
eyen-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EYEN
EYENOVIA, INC. Stock $eyen

2024 Q1 Form 10-K Financial Statement

#000141057824000226 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYEN EYENOVIA, INC. Stock $eyen

2024 Q1 Form 10-K Financial Statement

#000141057824000226 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EYEN
EYENOVIA, INC. Stock $eyen